Treatment with oral ubrogepant (Ubrelvy) during the migraine prodrome led to more patients being able to function normally, a prespecified secondary endpoint analysis of the phase III PRODROME trial ...
Absence of photophobia at 2 hours postdose occurred in 19.5 and 12.5% of ubrogepant- and placebo-treated events, respectively. HealthDay News — Ubrogepant during the prodromal phase of migraine may ...
The researchers found that after treatment of qualifying prodrome events, participants after ubrogepant treatment had a significantly greater ability to function normally over 24 hours than those ...
Please provide your email address to receive an email when new articles are posted on . A higher percentage of patients with migraine who received ubrogepant — an experimental treatment — experienced ...
Please provide your email address to receive an email when new articles are posted on . The study included 518 adults aged 18 to 75 years with at least a 1-year history of migraine. Adverse events ...
On the heels of favorable results from the phase 3 ACHIEVE-I trial, which were presented last week at the American Academy of Neurology (AAN) 2018 Annual Meeting, topline results from the phase 3 ...
(CNN) -- A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of ...
Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose. Ubrogepant has been shown to relieve migraine pain and ...
A new medication billing itself as a potential "innovative" solution to incurable migraines passed a large-scale clinical trial this week. The pill, called ubrogepant, currently is being trial tested ...
Allergan's ubrogepant is on a roll—the oral CGRP drug has hit the mark in a second phase 3 migraine trial, cementing the company's plans to file for approval in 2019. The 1,686-patient study tested a ...
The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of acute migraine to alleviating common prodromal symptoms of migraine ...
(CNN) -- A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results